Y-mAbs Therapeutics, Inc. (YMAB) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Lexicon Pharmaceuticals, Inc.

IGM Biosciences, Inc.

scPharmaceuticals, Inc.

Y-mAbs Therapeutics, Inc.

Ocular Therapeutix, Inc.

Vanda Pharmaceuticals, Inc.

AC Immune SA

Compass Therapeutics, Inc.

Inozyme Pharma, Inc.

Atea Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc.

Why is Y-mAbs Therapeutics, Inc. ?

Positive results in Jun 25

NET PROFIT(Q) Highest at USD -3.24 MM
RAW MATERIAL COST(Y) Fallen by 0.78% (YoY)
OPERATING PROFIT(Q) Highest at USD -5.55 MM

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -37.34%, its profits have fallen by -30.3%

Rising Promoter Confidence

Promoters have increased their stake in the company by 0.83% over the previous quarter and currently hold 12.12% of the company
Promoters increasing their stake is a sign of high confidence in the future of the business

Underperformed the market in the last 1 year

Even though the market (S&P 500) has generated returns of 14.72% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -37.34% returns

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Y-mAbs Therapeutics, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Y-mAbs Therapeutics, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Y-mAbs Therapeutics, Inc.

-37.34%

-0.23

125.54%

S&P 500

12.66%

0.74

20.01%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

143.95%

EBIT Growth (5y)

12.08%

EBIT to Interest (avg)

-72.19

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.67

Sales to Capital Employed (avg)

0.88

Tax Ratio

1.05%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

71.67%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.67

EV to EBIT

-5.80

EV to EBITDA

-5.88

EV to Capital Employed

6.04

EV to Sales

2.02

PEG Ratio

Dividend Yield

ROCE (Latest)

-104.17%

ROE (Latest)

-31.56%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Bullish (Daily)

KST

Bullish

Bearish

Dow Theory

No Trend

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

11What is working for the Company

NET PROFIT(Q)

Highest at USD -3.24 MM

RAW MATERIAL COST(Y)

Fallen by 0.78% (YoY

OPERATING PROFIT(Q)

Highest at USD -5.55 MM

PRE-TAX PROFIT(Q)

Highest at USD -3.23 MM

EPS(Q)

Highest at USD -0.07

-3What is not working for the Company

CASH AND EQV(HY)

Lowest at USD 122.6 MM

DEBT-EQUITY RATIO (HY)

Highest at -67.63 %

NET SALES(Q)

At USD 19.52 MM has Fallen at -11.91%

Here's what is working for Y-mAbs Therapeutics, Inc.

Net Profit

Highest at USD -3.24 MM and Grown

In each period in the last five periods

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (USD MM)

Operating Profit

Highest at USD -5.55 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (USD MM)

Pre-Tax Profit

Highest at USD -3.23 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Pre-Tax Profit

At USD -3.23 MM has Grown at 54.69%

over average net sales of the previous four periods of USD -7.13 MM

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit

At USD -3.24 MM has Grown at 54.11%

over average net sales of the previous four periods of USD -7.06 MM

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

EPS

Highest at USD -0.07

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Raw Material Cost

Fallen by 0.78% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Y-mAbs Therapeutics, Inc.

Net Sales

At USD 19.52 MM has Fallen at -11.91%

over average net sales of the previous four periods of USD 22.16 MM

MOJO Watch

Near term sales trend is negative

Net Sales (USD MM)

Cash and Eqv

Lowest at USD 122.6 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio

Highest at -67.63 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio